Business Model
ToloBio is eager to collaborate with innovative stakeholders across the CRISPR molecular diagnostics upstream and downstream industrial chain. We propose a model of project co-creation or joint development to shape the future together.
Tolo Biotechnology is willing to create the future together with the innovative subjects in the upstream and downstream industrial chain of CRISPR molecular diagnostics in the mode of project co-creation or joint development.
Patent License
ToloBio initially identified the efficient "trans-cleavage activity" of the CRISPR-Cas12 protein. Leveraging this discovery, the company developed the HOLMES (one-HOur Low-cost Multipurpose highly Efficient System) nucleic acid rapid detection platform. In comparison to traditional molecular diagnostic technologies, CRISPR-Cas12-based detection technologies offer notable benefits, including high sensitivity, specificity, rapidity, and convenience. These attributes have led to their recognition as "the next-generation molecular diagnostic technology" by the journal "SCIENCE". Consequently, CRISPR-based diagnostic technologies hold great promise for applications in various fields such as pathogen detection, genetic disease screening, and precision medicine.
ToloBio holds methodological patents for Cas12-based nucleic acid detection. In 2020, ToloBio entered into an agreement with Sherlock Biosciences for a "Patent Cross-licensing" collaboration on Cas12 and Cas13 diagnostic technologies in the U.S. and China. Subsequently, in November 2022, ToloBio and Sherlock Biosciences expanded their collaboration by signing a global CRISPR diagnostic "Patent Cross-licensing" agreement. This agreement granted co-exclusive rights to Cas12 and Cas13 CRISPR diagnostic methods in markets outside of the U.S. and China.
Cas12 Series
AU2016278990B2
Novel CRISPR enzymes and systems
CN108513582B
新型CRISPR酶以及系统
CN109207477B
CRISPR酶以及系统
HK1220726A1
新的CRISPR酶和系統
HK1253001A1
新型CRISPR酶以及系统
HK40011328A1
新型CRISPR酶以及系統
JP6898865B2
新規CRISPR酵素及び系
MX377162B
NUEVAS ENZIMAS Y SISTEMAS CRISPR
RU2737537C2
НОВЫЕ ФЕРМЕНТЫ И СИСТЕМЫ CRISPR
TWI758251B
新型ＣＲＩＳＰＲ酶以及系統
US9790490B2
CRISPR enzymes and systems
US10669540B2
CRISPR enzymes and systems
US10648020B2
CRISPR enzymes and systems
US11091798B2
CRISPR enzymes and systems
CN110551800B
一种耐高温Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒
CA3102438C
Use of high-temperature-resistant cas protein, and method and reagent kit for detecting target nucleic acid molecule
CN108513582B
新型CRISPR酶以及系统
ZA202008068B
Use of high-temperature-resistant cas protein, and method and reagent kit for detecting target nucleic acid molecule
ZA202000682B
Application of cas protein, method for detecting target nucleic acid molecule and kit
MOJ004548C
一種Cas蛋白的用途及靶標核酸分子的檢測方法和試劑盒。
CN107488710B
一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒
Cas13 Series
AU2017283713B2
Type VI CRISPR orthologs and systems
NO3551753B1
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS
KR102454284B1
신규 CAS13B 오르소로그 CRISPR 효소 및 시스템
US10266886B2
CRISPR effector system based diagnostics
AU2016342038B2
Type VI-B CRISPR enzymes and systems
AU2018234825B2
Novel CAS13B orthologues CRISPR enzymes and systems
US10266887B2
CRISPR effector system based diagnostics
KR102185464B1
신규 CAS13B 오르소로그 CRISPR 효소 및 시스템
EP3551753B1
Crispr effector system based diagnostics
Other
CN216187183U
一种核酸样本存储装置
CN216192288U
一种电浸润微流控核酸扩增检测装置
CN215997965U
一种病毒保存管灭菌消毒装置
CN216005861U
一种断电续检的便携式等温扩增检测系统
CN215887004U
一种核酸自动提取装置
CN215884669U
一种病毒保存管存放架
CN215886978U
一种全自动核酸离心提取装置
CN215887035U
一种等温核酸扩增系统装置安装架
CN215877989U
一种基于CRISPR技术的离心式微流控芯片
CN215878020U
一种荧光定量PCR检测用工作台
CN215887006U
一种病毒运送保存管
CN215887021U
一种实时荧光定量PCR检测系统
CN215555339U
一种病毒保存管用存放箱
CN106319033B
一种检测染色体异常以及重组位点DNA序列的方法
Technical Cooperation
01
HOLMES
Molecular Diagnostic Platform
02
HOLMES v2
Molecular Diagnostic Platform
03
SENA
COVID-19 Rapid Test
04
TB-QUICK
Tuberculosis Rapid Test
HOLMES
In 2017, ToloBio found that CRISPR-Cas12 protein has “trans-cleavage activity.” This led to the creation of HOLMES, a nucleic acid rapid detection method. HOLMES has vast applications like infectious disease detection, genetic disease screening, and home self-testing.
HOLMES v2
We've employed a thermostable CRISPR-Cas12b for a one-step system, merging isothermal amplification and CRISPR detection. This reduces contamination risk and streamlines the process, shortening testing time. This highlights HOLMES v2's potential for diverse molecular diagnostics.
SENA
ToloBio created SENA (Specific Enhancer for detection of PCR-amplified Nucleic Acids), a CRISPR-based technology, to address the “gray area” problem in qPCR. SENA rectifies incorrect diagnoses, enhancing accuracy and dependability.
TB-QUICK
Rapid, sensitive, and affordable diagnosis of M. tuberculosis is vital for controlling TB. ToloBio innovated a new TB DNA detection method, merging LAMP with CRISPR-Cas12b detection. This approach allows rapid and sensitive TB detection, offering a promising solution for TB diagnosis.
